CD4 and B-cell chronic lymphocytic leukemia: Ibrutinib has been shown to reduce the immunosuppressive properties of chronic lymphocytic leukemia (CLL) cells and decrease the ratio of regulatory T cells to CD4 + T cells, thereby enhancing the efficacy of ibrutinib when combined with other immunotherapy methods [197].